DBV Technologies (NASDAQ:DBVT) Shares Gap Up – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) gapped up prior to trading on Wednesday . The stock had previously closed at $22.50, but opened at $24.79. DBV Technologies shares last traded at $23.9920, with a volume of 106,535 shares changing hands.

Analyst Ratings Changes

Several research firms recently commented on DBVT. Wall Street Zen downgraded DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp raised their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Wednesday, December 17th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research note on Thursday, December 18th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DBV Technologies in a report on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, DBV Technologies presently has an average rating of “Moderate Buy” and a consensus target price of $35.38.

DBV Technologies Trading Down 0.9%

The firm’s fifty day simple moving average is $19.35 and its two-hundred day simple moving average is $14.39. The company has a market capitalization of $853.80 million, a price-to-earnings ratio of -4.11 and a beta of -0.98.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total value of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares in the company, valued at $30,601,116.11. The trade was a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 3,369,627 shares of company stock valued at $15,489,908 in the last quarter. 1.44% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Vivo Capital LLC acquired a new position in shares of DBV Technologies in the 2nd quarter worth approximately $9,659,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the 2nd quarter valued at $9,649,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies during the 2nd quarter worth about $9,315,000. Finally, UBS Group AG boosted its holdings in DBV Technologies by 165,347.3% during the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock valued at $4,694,000 after acquiring an additional 244,714 shares during the period. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.